RxDoctor Payments Data

Julio Rojas-Martinez

Neurology · San Francisco, CANPI 1144548751

Payments from drug & device makers

What this record shows

That places this record below the midpoint for neurology clinicians in CA, where the typical reported total is $885.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$1,561,017in research payments, 2019–2025

Across 76 payments — averaging $20,540 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1.3M
  • Eisai Inc.$274K
  • Amylyx Pharmaceuticals, Inc.$36K

How this compares

$0 in reported general payments places this provider in the 5th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$22,530
Medicare patients
120
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rivastigmine36$8,995
Donepezil Hcl131$1,558
Escitalopram Oxalate46$669
Galantamine Hbr13$566
Trazodone Hcl58$465
Memantine Hcl12$314
Citalopram HbrCitalopram Hydrobromide45$285
Carbidopa-LevodopaCarbidopa/Levodopa13$213
RivastigmineRivastigmine Tartrate11$175

Paid to pharmacies, not to this prescriber.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →